Vetter Continues to Lead the Industry in Sustainability Initiatives

15 June 2023 | Thursday | News

Globally-operating CDMO publishes annual sustainability report

  • Report now includes Scope 3 emissions
  • Employee-driven social responsibility takes precedence as driving force for sustainability activities
  • Goal to reduce total emissions globally by ten percent by 2029

-Vetter, one of the world's leading Contract Development and Manufacturing Organizations (CDMO), is consistently pursuing improvements to its sustainability strategy. The globally-operating company released its second-annual sustainability report. For the first time, the pharmaceutical service provider headquartered in Ravensburg, Germany, also reports its Scope 3 emissions and shows its CO2 balance according to the requirements of the international Greenhouse Gas Protocol. Adding to its dynamic growth, the company was able to significantly reduce electricity consumption and CO2 emissions per euro of gross value added compared to the previous year. By 2029, the total emissions in relation to gross value added are to be reduced by ten percent compared to the base year 2019.

“Hardly any other topic concerns our company as holistically as sustainability. Functioning supply chains are a non-negotiable for us. With our sustainability report, we make our measures, successes and goals even more transparent. This gives our partners confidence in implementing their own sustainability goals.”

Sustainability creates resilience and reliability in the supply chain

"We support our customers in the production of high-quality and vital medicines for their patients worldwide,” says Managing Director Thomas Otto. “Hardly any other topic concerns our company as holistically as sustainability. Functioning supply chains are a non-negotiable for us. With our sustainability report, we make our measures, successes and goals even more transparent. This gives our partners confidence in implementing their own sustainability goals."

With 100 percent green electricity, the CDMO has been a sustainability pioneer in the pharmaceutical industry since 2014. Since then, Vetter has massively advanced the expansion and conversion of the individual company sites in the areas of renewable energies, resource efficiency and circular economy.

"Without the support from all levels of the company, and without the dedicated commitment of the management and the owner families, we would be nowhere near where we are today in terms of sustainability," added Henryk Badack, Senior Vice President Technical Services and Internal Project Management.

Focus on social responsibility

Assuming responsibility for employees and making a sustainable contribution to society is an important pillar of Vetter’s sustainability strategy. A comprehensive health management with target-group-oriented offers for employees in different life situations is as much a part of Vetter’s sustainability commitment as is the promotion of high-value training and development opportunities. For example, Vetter offers all employees a free supplementary company health insurance to fund additional services that are often not covered by statutory health insurance.

Furthermore, the CDMO secured first place in the 2022 Sustainable Impact Award in the category of Social Impact on Employees, which is awarded to the most attractive medium-sized employers with a focus on employee satisfaction.

Enhanced brand identity

Simultaneously, the pharmaceutical service provider is presenting its enhanced brand identity. According to Managing Director Peter Soelkner, “Our company is characterized by sustained, strong growth. Our mission is to improve the quality of life of patients worldwide and our aspiration is reliability – for our customers, suppliers and employees. In short: at all levels. With our newly launched enhanced brand, we want to make this promise even clearer – through strong corporate values and embedded in a dynamic design. Our new image authentically conveys what Vetter is all about and what we stand for."

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close